title: Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues.
abstract: Coronary artery disease remains a major health problem worldwide. Since introduction of percutaneous transluminal coronary angioplasty and stents, much progress has been made. Percutaneous coronary intervention, however, has been limited by restenosis (repeat obstruction of arteries that have been previously treated. Introduction of drug-eluting stents (DESs) in April 2003 was a major breakthrough in preventing restenosis. In March 2003, The Society for Cardiovascular Angiography and Interventions (SCAI) published a position statement on the clinical implications of DESs, recommending an evidence-based adoption strategy. Subsequently, in May 2003, SCAI formed a multidisciplinary Drug Eluting Stent (DES) Task Force to address the significant nonclinical ramifications posed by DESs: medicolegal, financial, and access to care. The Task Force included representatives from physician societies, industry, academia, the reimbursement community, and health policy organizations. The resultant report presents analyses, options, and recommendations regarding those nonclinical issues based on the collective experience and knowledge of the Task Force members. The Task Force trusts that this report will be of value to the diverse constituencies involved with introduction of this important new technology.
authors.affiliation: MetroHealth Medical Center, Cleveland, Ohio 44109, USA. jhodgson@TSG-ED.com
authors.forename: John McB
authors.initials: JM
authors.lastname: Hodgson
authors.forename: Randy K
authors.initials: RK
authors.lastname: Bottner
authors.forename: Lloyd W
authors.initials: LW
authors.lastname: Klein
authors.forename: Howard T
authors.initials: HT
authors.lastname: Walpole
authors.forename: David J
authors.initials: DJ
authors.lastname: Cohen
authors.forename: Donald E
authors.initials: DE
authors.lastname: Cutlip
authors.forename: Randolph B
authors.initials: RB
authors.lastname: Fenninger
authors.forename: Brian G
authors.initials: BG
authors.lastname: Firth
authors.forename: Dan
authors.initials: D
authors.lastname: Greenberg
authors.forename: Ilona
authors.initials: I
authors.lastname: Kalisky
authors.forename: Thomas
authors.initials: T
authors.lastname: Meskan
authors.forename: Wayne
authors.initials: W
authors.lastname: Powell
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: James P
authors.initials: JP
authors.lastname: Zito
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Clark
mesh_terms: D026683:Advisory Committees / Q000191:economics / Q000331:legislation & jurisprudence; D015906:Angioplasty, Balloon, Coronary / Q000191:economics / Q000331:legislation & jurisprudence; D019917:Blood Vessel Prosthesis Implantation / Q000191:economics / Q000331:legislation & jurisprudence; D020099:Coated Materials, Biocompatible / Q000191:economics / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000191:economics / Q000331:legislation & jurisprudence; D003324:Coronary Artery Disease / Q000628:therapy; D003362:Cost-Benefit Analysis / Q000191:economics; D006287:Health Planning Guidelines; D006297:Health Services Accessibility / Q000191:economics / Q000331:legislation & jurisprudence; D006801:Humans; D012955:Societies, Medical / Q000191:economics / Q000331:legislation & jurisprudence; D015607:Stents / Q000191:economics; D014481:United States
chemical_list: D020099:Coated Materials, Biocompatible